Aptar Q1 sales rise 11%, beat estimates; EPS falls as prescription sales decline

Overview

• Drug delivery and dispensing firm's Q1 sales rose 11%, beating analyst expectations

• Adjusted EPS for Q1 beat consensus but declined 8% yr/yr

• Company returned $131 mln to shareholders via buybacks and dividends

Outlook

• Aptar expects Q2 2026 adjusted EPS of $1.32 to $1.40

• Company anticipates growth across all segments in Q2, except for emergency medicine destocking in Pharma

• Aptar remains mindful of potential supply-chain uncertainties in the coming quarter

Result Drivers

• INJECTABLES DEMAND - Pharma injectables division delivered strong double-digit growth, driven by demand for GLP-1, biologics and antithrombotics

• EMERGENCY MEDICINE DESTOCKING - Prescription division sales declined due to reduced sales in emergency medicine category and tough comparison with strong prior-year quarter

• BEAUTY AND CLOSURES VOLUME GROWTH - Consumer dispensing segment saw volume growth in Beauty and Closures, supported by demand in fragrance and beverage applications

Company press release: ID:nBwNDdFna

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the non-paper containers & packaging peer group is "buy"

• Wall Street's median 12-month price target for Aptargroup Inc is $153.00, about 24.5% above its April 29 closing price of $122.90

• The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 22 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.